Cite
Schettini F, Santo I, Rea CG, et al. Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series. Mol Clin Oncol. 2020;12(5):456-460doi: 10.3892/mco.2020.2016.
Schettini, F., Santo, I., Rea, C. G., Viggiani, M., Buono, G., Angelis, C., Cardalesi, C., Lauria, R., Giuliano, M., Forestieri, V., Thomas, G., Maione, P., Limite, G., Accurso, A., Malorni, L., Placido, S., & Arpino, G. (2020). Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series. Molecular and clinical oncology, 12(5), 456-460. https://doi.org/10.3892/mco.2020.2016
Schettini, Francesco, et al. "Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series." Molecular and clinical oncology vol. 12,5 (2020): 456-460. doi: https://doi.org/10.3892/mco.2020.2016
Schettini F, Santo I, Rea CG, Viggiani M, Buono G, Angelis C, Cardalesi C, Lauria R, Giuliano M, Forestieri V, Thomas G, Maione P, Limite G, Accurso A, Malorni L, Placido S, Arpino G. Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series. Mol Clin Oncol. 2020 May;12(5):456-460. doi: 10.3892/mco.2020.2016. Epub 2020 Mar 11. PMID: 32257203; PMCID: PMC7087462.
Copy
Download .nbib